Growth Metrics

ENDRA Life Sciences (NDRA) Free Cash Flow (2016 - 2025)

ENDRA Life Sciences has reported Free Cash Flow over the past 6 years, most recently at -$2.7 million for Q4 2021.

  • Quarterly Free Cash Flow fell 24.08% to -$2.7 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$11.2 million through Dec 2021, down 3.19% year-over-year, with the annual reading at -$5.2 million for FY2025, 29.89% up from the prior year.
  • Free Cash Flow was -$2.7 million for Q4 2021 at ENDRA Life Sciences, up from -$2.7 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$236274.0 in Q1 2017 and troughed at -$3.5 million in Q2 2020.
  • The 5-year median for Free Cash Flow is -$2.1 million (2020), against an average of -$2.1 million.
  • Year-over-year, Free Cash Flow crashed 937.73% in 2018 and then grew 18.9% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at -$1.4 million in 2017, then tumbled by 38.3% to -$1.9 million in 2018, then fell by 2.28% to -$1.9 million in 2019, then dropped by 9.87% to -$2.1 million in 2020, then fell by 24.08% to -$2.7 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Free Cash Flow are -$2.7 million (Q4 2021), -$2.7 million (Q3 2021), and -$2.8 million (Q2 2021).